Introduction
Nucleic acid-based aptamers have gained prominence as a promising platform for targeted drug delivery due to their ability to serve either as a therapeutic agent or as an evolvable targeting modality [1] [2] [3] . Nucleic acid-based aptamers consist of in vitro selected oligonucleotides involving libraries of up to 10 16 randomly synthesized sequences through a method termed SELEX (Systematic demonstrated. In this construct the antagonistic aptamer provided receptor specificity while the miRNA moiety resulted in the silencing of gene expression. In one such approach Esposito et al. linked the GL21.T aptamer that is specific to Axl, a receptor tyrosine kinase (an oncogene overexpressed in several human cancers), to the tumor suppressor let-7g miRNA, resulting in the GL21.T-let chimera (Fig. 1A) [16] . Application of the GL21.T-let chimera to mice bearing A549 (Axl + ) tumors downregulated let-7g target genes leading to apoptosis, decreased cell proliferation, and a reduction in tumor size. Using different conjugation strategies and a combination of additional aptamers (e.g., a prostate specific membrane antigen aptamer) and miRNA sequences (e.g., miR-16) the authors demonstrated the versatility of their approach.
The aberrant regulation of certain miRNAs during malignant transformation makes them potential therapeutic targets for inhibition using antimiRs [17] . AntimiRs are synthetic oligonucleotides that base pair with corresponding miRNAs. Such miRNAs complexed with antimiRs do not bind target mRNAs resulting in an increase in the expression of the target gene repressed by the miRNA [18] . Recently, Pofahl et al. reported on the delivery of an antimiR, targeting the miR-21, through the nucleolin-binding aptamer (AS1411) [19] .
In a follow up study the de Franciscis' group used the GL21.T aptamer to deliver RNA-based antimiRs inhibiting the cancer progression-associated miRNA miR-222 (Fig.  1B) [20] . Treatment of Axl or platelet-derived growth factor receptor β expressing cells with the GL21.T-222 or Gin4.T-222 conjugates resulted in the decrease of target miR-222 levels and an increase of the miR-222 target proteins. Again, as in previous work, the authors observed a synergistic effect of the GL21.T-222 conjugate on the reduction of cell migration and an increase in the sensitivity to temozolomide induced cell death. Interestingly, when the authors intended to enhance the antagonizing potential using two antimiR-222 moieties connected in tandem, no additive effect was detected. In contrast, employing an aptamer with two different antimiRs (antimiR-222 and antimiR-10b) led to the reduction of the two respective miRNAs and increased target protein levels.
In a related study three different strategies for conjugating miRNAs (miR-126) to a transferrin receptor aptamer (TfRA) were tested (Fig. 1C) [21] . In the first study, a chimera (Ch1) consisting of the mature miR-126-5p covalently linked to TfRA and base-paired to miR-126-3p was used. For the Ch2 chimera used in the second study, the TfRA contained a "stick" sequence complementary to a stick part linked to the mature miR-126-5p annealed to miR-126-3p. The third chimera (Ch3) was similar to Ch2 but the complementary stick sequence was base paired with the precursor of miR-126 (pre-miR-126). All three constructs were internalized by endothelial cells, but only treatment with aptamer-pre-miR-126 resulted in the reduction of the VCAM-1 target and an increase in angiogenesis. Also, there were differences in the response of tumor cell lines to treatment with Ch3. It is unclear why no biological function was detected with the other two chimeras.
Zhou et al. selected an aptamer targeting human B-cell activating factor receptor (BAFF-R) to deliver siRNAs to non-Hodgkin's lymphoma cells [22] . Activation of BAFF-R upregulates pathways leading to enhanced B-cell proliferation, but neither aptamers R1 or R14 activated BAFF-R. Down-regulation of STAT3 was previously demonstrated to inhibit growth of lymphoma tumor cells. To deliver siRNAs corresponding to STAT3 two pairs of AptsiRNA chimeras were designed. In the first pair, the sense or antisense strands were linked to an aptamer involving an eight-nucleotide linker (Fig. 1D ). In the second pair of chimeras, the siRNAs were connected to the aptamer through stick sequences (Fig. 1D ). All chimeras led to the silencing of STAT3 expression, albeit down-regulation mediated by Apt-linker-siRNAs was more profound than using Apt-stick-siRNA chimeras.
Blocking of a cellular receptor with an aptamer represents a plausible strategy to prevent binding and entry of viruses into host cell. Similarly, binding of aptamers to viral glycoproteins decreases virus attachment to target membrane proteins [23, 24] . The first approach also offers the potential to bolster antiviral effects through aptamer delivery of siRNAs targeting viral and virus-required host genes.
In two recent studies Zhou et al. investigated functional in vivo delivery of anti-HIV-1 siRNAs via RNA aptamers targeting HIV-1 glycoprotein gp120 or human CCR5 (C-C chemokine receptor type 5). In the first study, an aptamer targeting HIV-1 glycoprotein gp120 and a siRNA were joined via a "sticky bridge" [25] . Complementary sticky bridge strands were connected to the 3′-end of the aptamer and to one of the antisense or sense siRNA sequences using a carbon linker. To prevent the creation of viral escape mutants, both virus-encoded and cellular transcripts were targeted including the viral transcripts encoding HIV-1 tat and rev, and transcripts encoding CD4 that is required for HIV-1 entry and transportin 3 (TNPO3) that is required for viral integration. The intravenous injection of an anti-gp120 Apt-siRNAs mixture to humanized mice downregulated expression of all three genes targeted. Most of the mice treated had undetectable viral loads up to three weeks after the final treatment. Moreover, viral rebounds observed three months after the end of the first However, suppression of HIV-1 replication was stronger when G-3-TNPO3 siRNA was applied [26] .
Recent results using a humanized murine model suggest that hydroxyethyl cellulose gel-formulated Apt-siRNA chimeras may also be used to prevent HIV infection in the female genital tract [27] . Mice that received CD4 + specific aptamers with covalently linked siRNAs corresponding either to the host CCR5 gene or the viral gag/vif sequences up to four days before intravaginal exposure to virus showed no evidence of infection. In the following 10 weeks no p24 antigen or viral RNA was detected in their plasma and the number of CD4 + cells remained unchanged. Even administration of CD4 aptamer-gag/vif siRNAs for just four hours post exposure protected some mice completely.
A relatively simple idea of how to improve the intracellular uptake of siRNAs due to the increased chances of contact between aptamers and receptors was outlined by Yoo et al. who "chained" a DNA aptamer against Mucin 1 and anti GFP or Bcl-2 siRNA conjugates in a multivalent comb-like structure [28] . The backbone of the rod-like nanoparticle was created by linear connection of antisense siRNA strands via thiol-maleimide coupling. Subsequently, multiple copies of DNA aptamers-sense siRNA conjugates were annealed to antisense siRNA chains (Fig. 1E ). Compared to monomeric and dimeric Apt-siRNA, multimeric Apt-siRNA labeled with the red fluorescent dye POPO-3 in the context of MUC1-positive human MCF-7 breast cancer cells produced the strongest fluorescence signal. However, despite efficient internalization no apparent GFP knock-down was detected, possibly pointing to poor endosomal escape.
Aptamer-mediated delivery of catalytically active nucleic acids
DNAzymes are single stranded DNA molecules that are catalytically active on nucleic acid substrates catalyzing a variety of reactions like RNA cleavage, ligation, DNA phosphorylation etc. Several studies have already examined the ability of DNAzymes to destroy specific mRNAs [29] .
The first aptamer-mediated targeted delivery of a DNAzyme was recently described by Subramanian et al. who annealed a nucleolin binding DNA aptamer (AS1411) to a survivin specific DNAzyme [30] . Nucleolin is able to rapidly translocate from the cell surface to the nuclei of cells which makes it an ideal transport vehicle to reach the nucleus. Survivin is a member of a protein family that promotes survival and proliferation of cancer cells [31] . Surprisingly, the WERI-Rb1 cell line with the internalized chimeric conjugate showed decreases in survivin mRNA levels and cell proliferation similar to cells treated with the aptamer alone. Because the nucleolin aptamer by itself also triggered functional responses it is tempting to speculate that its binding to nucleolin may have downregulated survivin expression.
Aptamer-mediated delivery of spliceswitching oligonucleotides
Splice-switching oligonucleotides (SSOs) are singlestranded oligonucleotides that target nuclear pre-mRNA molecules to alter mRNA splicing resulting in alternative protein isoforms [32] . Conjugation of SSOs to an aptamer whose target protein (e.g. nucleolin) is translocated to the nucleus may enhance the potential therapeutic utility of SSOs.
In a proof-of-principle experiment, Kotula et al. used a prostate cancer cell line expressing a luciferase reporter construct with a premature stop codon. When treated with the nucleolin Apt-luciferase SSO chimera the percentage of repaired mRNA increased by 13% over the baseline as seen in untreated cells but only by 5% compared with cells treated with the luciferase SSOs only. One major advantage of SSO-based therapies is that only a small percentage of repaired pre-mRNA often times is sufficient to generate a phenotypic effect [33] .
Bispecific aptamer conjugates
Linking various cell-specific aptamers to a DNA scaffold provides an appealing strategy to direct cellcell interactions [34] . For example, bispecific aptamer conjugates have the potential to cross-link tumor cells with immune cells and to activate the cognate receptors. The 4-1BB receptor plays a crucial role in the survival and expansion of activated CD8 + T cells and their differentiation into memory cells. The lack of the 4-1BB ligand in tumors inspired Gilboa's group to conjugate the agonistic 4-1BB aptamer to an aptamer targeting VEGF (Fig. 1F) [35] . VEGF is secreted into the stroma of many tumors, which makes it a versatile target. Vaccination and co-treatment with the VEGF4-1BB aptamer effectively inhibited tumor growth while conjugates alone or vaccination had a minimal effect. Vaccination with a mixture of VEGF and 4-1BB aptamers also had no effect. Similar outcomes were observed in the context of four unrelated tumor models.
Aptamer-mediated delivery of decoys
Decoys are synthetic, double-stranded oligonucleotides that selectively inhibit the transcriptional activity of DNA binding proteins by competing for binding to their specific target sequences present in promoters and enhancers [36] .
Cell specific delivery of decoys through aptamers was recently demonstrated by Porciani et al. [37] . In their model system they evaluated the ability of an RNA aptamer binding to human transferrin receptor to deliver a decoy designed to mimic the κB consensus promoter sequence recognized by NF-κB. Various stimuli such as carcinogenesis, inflammatory agents, or chemotherapeutic drugs activate NF-κB resulting in its translocation from the cytoplasm to the nucleus where it promotes transcription of antiapoptotic genes. To achieve a synergistic effect, Porciani et al. elongated the aptamer with a doxorubicine (Dox) binding G-C rich double stranded DNA tail that hybridized to an antitail sequence conjugated through a disulfide linker to a NF-κB self-complementary decoy sequence (Fig. 1G) . Internalization of the Apt-NF-κB decoy by pancreatic carcinoma MIA PaCa-2 cells led to the reduction of NF-κB translocation from the cytoplasm to the nucleus upon TNF-α stimulation. Subsequently, simultaneous delivery of Dox and inhibition of NF-κB resulted in higher cytotoxicity than using an aptamer-Dox without decoy.
3 Aptamers as parts of multifunctional self-assembled RNA/DNA nanostructures DNA and RNA nanoparticles are programmable engineered 3D nanoscaffolds that benefit from the unique ability of nucleic acids to form canonical and non-canonical base pairings leading to a diverse set of structural motifs. The simplicity of their primary structure allows selfassembly into compact and stable structures with precise control over the size, geometry, and composition of the final nanoparticle [38] . Research carried out in recent years showed that DNA and RNA nanoparticles are suitable as scaffolds for the delivery of various modules carrying different functional properties like aptamers and antisense oligonucleotides. In addition to intrinsic nucleic acid-based functional moieties, other chemical components can be associated with nanoparticles such as fluorophores, chemotherapeutics, etc. [39] [40] [41] .
The origin of RNA nanotechnology dates back to 1998, but surprisingly, very few groups reported targeted delivery of self-assembled RNA nanoparticles through aptamers [42] . In pioneering work Guo et al. treated CD4-overexpressing T cells with a RNA nanoparticle consisting of a dimer of the packaging RNA (pRNA) derived from the DNA-packaging motor of bacteriophage phi29, a CD4 specific aptamer and a siRNA complementary to survivin mRNA ( Fig. 2A) [43] . Although, survivin mRNA or protein levels were not investigated, the decrease in cell viability observed was due to the targeted delivery of survivin siRNA, because incubation of cells with survivin pRNAsiRNA monomers alone had no effect on cell viability. Since the intermolecular binding domain and the doublestranded helical domain at the 5′ and 3′ ends of pRNA fold independently exchange of the end helical region for an aptamer or siRNA did not affect the pRNA structure provided that the two strands were base-paired. The left-and righthand loops of the interlocking domain were shown to pair with other monomers to form multimeric pRNAs [12] . More recently, Hu et al. used this feature to create dimeric pRNAs (FRS-NPs) where the helical domain of one monomer was replaced with the FB4 aptamer directed against the mouse transferrin receptor and the helical domain of the second monomer with an siRNA targeting ICAM-1 mRNA. Treatment of an in vitro inflammatory cell model with FRS-NPs reversed the increase of ICAM-1 expression and blocked the adhesion of monocytes [44] .
In a recent study Afonin et al. designed artificial multifunctional RNA nanoparticles and examined their capacity to silence multiple HIV-1 genes using siRNAs, to deliver newly developed RNA-DNA hybrids into cells and to target cells using aptamers [41] . Hexameric nanorings allowed combinatorial embedment of up to 6 different functionalities, including aptamers and siRNAs, basepaired to the ring scaffold (Fig. 2B) . To demonstrate that nanorings can be targeted to specific cells, particles containing up to five copies of the J18 RNA aptamer binding to the human epidermal growth factor receptor (EGFR) were assembled [45] . One biotinylated oligonucleotide that was part of the nanoring structure served as a coupling system allowing fluorescent visualisation through streptavidin conjugated to phycoerythrin. Nanorings with higher numbers of aptamers per nanoparticle provided a higher binding affinity to target cells. The internalization and functional effects of siRNAs bound to aptamer-nanorings were not studied.
Although DNA lacks the functional versatility of RNA, self-assembled DNA nanoparticles have been successfully used as a simple scaffold with the capacity to bind to the folate receptor and to display antisense DNA oligonucleotides or to deliver siRNAs [46, 47] . Moreover, DNA scaffolds are suitable to deliver chemotherapeutics intercalated into its duplex structure as shown by Tan's group that created the so called Apt-tethered DNA nanotrains (Apt-ntr) consisting of the sgc8 or AS1411 aptamers followed by a long linear dsDNA nanostructure (Fig. 2C) [48] . Application of Apt-ntr loaded with Dox in a mouse xenograft tumor model reduced tumor volumes more efficiently than free Dox and led to prolonged survival of treated mice. Furthermore, mice treated with Dox delivered in a targeted fashion experienced less weight loss compared to mice treated with "free" Dox, indicating that targeted delivery reduced side effects. In a parallel study Tan and coworkers photo-cross-linked 5' acrydite-modified oligonucleotides to form spherical DNA nanoparticles designed to deliver the MDR1-specific antisense oligonucleotides and Dox to kill drug resistant myelogenous leukemia K562/D cells [49] .
The DNA origami technique provides a powerful method to create custom DNA devices by folding multikilobase ssDNA scaffolds via interaction with "staple" oligonucleotides [50] . Besides building mere static structures, several groups explored the nanomechanical properties of DNA devices made of DNA origami regarding their ability to dynamically react on external stimuli [51] . Cell-specific delivery and logical release of cargo based on the specificity of the aptamers used was demonstrated by the Church group who created a nanorobot in the form of a hexagonal barrel consisting of two halves linked together by single-stranded scaffold hinges (Fig. 2D) [52] . Inspired by Andersen et al., this barrel was locked by two DNA aptamers present on one of the half-barrel domains and was base-paired to a partially complementary strand on the opposite domain [53] . After simultaneous recognition of target proteins (protein keys) by the two aptamers, the aptamer lock duplexes dissociated, and the nanorobot exposed its cargo hidden inside of the barrel. Payloads conjugated to the 5′ end of ssDNA oligonucleotides involved up to 12 complementary 3′ extended staple strands. To prove the functionality and robustness of the aptamer-encoded logic gating approach, six different robots were designed using pairwise combinations of aptamer locks from a set of three aptamer sequences: 41t, TE17, and sgc8c. Barrels loaded with fluorescently labeled Fab' fragments against human leukocyte antigens emitted a fluorescent signal only when antibody fragments were uncovered from the barrel interior after the two protein keys on the cell surface were matched to an aptamer pair. In mixed cell populations the robots displaying the proper aptamer locks bound almost exclusively to the target NKL cells and detected one target cell in a background of 10 6 receptor negative cells. In addition to cell labeling, nanorobots carrying a combination of antibodies triggered physiological response in targeted cells by inducing growth arrest in leukemic cells or promoting T-cell activation.
The prevalent strategy for creating DNA nanoparticles utilizes Watson-Crick base-pairing between individual DNA building blocks. In an alternative approach Zhou et al. created densely packed DNA particles with built-in multifunctional moieties that self-assembled through liquid crystallization to monodisperse structures without reliance on Watson-Crick base-pairing [54] . DNA concatemers consisting of multiple aptamer (sgc8) sequences and Dox loading were generated using rolling circle replication. The so-called Nanoflowers (NFs) specifically recognized target HeLa and CEM cells and subsequent treatment with Dox loaded NFs or free Dox led to a similar decrease in cell viability. However, Dox-NFs reduced the viability of control Ramos cells only modestly compared to free Dox.
Issues to be resolved
Delivery of nucleic acid-based therapeutics through aptamers poses several challenges including but not limited to the structural design, in vivo stability, immunogenicity, cellular uptake and endosomal escape.
Aptamer design
The selection of an optimal aptamer that is highly specific for its target in the native microenvironment (cell membrane) and that is endocytosed upon binding and released into the cytoplasm, is quite challenging. To approach this issue modified cell-based aptamer selection methods such as cell-internalization SELEX have been developed [55, 56] . It appears that the current strategies employed to link aptamers with a functional module preserves folding and consequently aptamer target affinity [16, 20, 22, 25] . Furthermore, the computational design of self-assembling nucleic acid nanoparticles allows assembling of individual functional parts on the scaffolds while preserving their proper folding [57] .
Sensitivity to nucleases
The sensitivity of nucleic acids to nucleases in vivo complicates their therapeutic use. However, incorporation of chemically modified nucleotides such as 2'-F pyrimidines and 2'-Ο Me nucleotides or the use of phosphorothioate internucleotide linkages significantly extends survival of nucleic acids without affecting their functionality [58] [59] [60] .
The self-assembled DNA/RNA nanocarriers adopt conformations that substantially differ from naturally occurring nucleic acids [61] . It is thus questionable to what extent a conclusion about their stability based on the knowledge of their building blocks can be drawn. To date several groups have reported that 3D DNA nanostructures of various shapes maintained their structural integrity up to 48 hours in the cytoplasm or lysosomes or when exposed to cell lysates, or nucleases [62] [63] [64] [65] . The relationship between stability and shape has shown that triangular nanostructures tend to be more fragile than tetrahedral structures [66] . The degradation kinetics of DNA box origami in serum have been investigated in real time with nanometer resolution. High-speed atomic force microscopy revealed that the half lives of 3D DNA box origami structures in 0.1 % serum is 62 ± 26 s and that destruction started with a rapid height collapse phase and a slow degradation phase that lasted from several minutes to half an hour [67] .
Clearance
Besides degradation by nucleases, circulation of nucleic acid-based therapeutics in the blood stream is challenged by their removal through size dependent extravasation and renal clearance. In addition to cellular factors, nanoparticle size, shape, and distribution of ligands on the nanoparticle were shown to influence the rate of cellular uptake [68] .
Immune responses
Following internalization nucleic-acid therapeutics are subject to the cellular innate immune surveillance system. Nucleic acids in the endolysosomal lumen are screened by nucleic acid-sensing Toll like receptors (TLRs) based on their structure and sequence (Fig. 3) [69] . Furthermore, many nonimmune cells (epithelial cells, fibroblasts) that do not express TLRs are able to trigger innate immune responses by a second line of sensors localized in the cytosol, suggesting that not all experimental settings may reveal the immunogenic potential of nanoparticle (Fig. 3) [70]. Interestingly, 2'-F and 2'-Ο Me modified nucleotides do not promote a defense reaction [71] . On the other hand the immunomodulatory properties of nucleic acids can be exploited to trigger innate immunity responses [72] [73] [74] .
Trafficking
The trafficking of an internalized aptamer bound to a receptor can be complex. For example, the endocytosed payload can end up being degraded in lysosomes, or exported out of the cell (Fig. 3) . Alternatively, it can escape from the endosome. The fate of the aptamer- Figure 3 : Trafficking of internalized nucleic-acid therapeutics. The aptamer RNA/DNA nanoparticle-receptor complex is internalized and distributed in a number of ways. Undesirable outcomes are recycling of the particle back to the cell surface, degradation in lysosomes or triggering of cellular defense reactions. Nucleic acids activate the innate immune system in the endosomal compartment through the TLRs that recognize ssRNA or dsRNA and unmethylated cytosine-guanosine (CpG) DNA motifs. Subsequent signalling cascades induce transcription of type I interferon (IFN) genes and genes encoding other inflammatory cytokines. Foreign RNA that reaches the cytoplasm is sensed by the cytosolic surveillance system, represented most notably by the retinoic acid inducible gene-I (RIG-I), 2'-5-oligoadenylate synthetase (OAS), RNase L and dsRNA-depended protein kinase R (PKR). RIG-I recognizes a triphosphate group at the 5' end of the RNA strands or short RNAs generated by RNase L. When bound to dsRNA, OAS converts ATP to 2'-5'-linked oligoadenylates that activate degradation of ssRNAs through RNase L. Binding of PKR to the dsRNA leads to suppression of translation. Ultimately, the transcription of type I IFN genes and proinflammatory cytokine genes is activated. For simplicity, many proteins involved in downstream signaling are omitted as well as proteins involved in cytosolic DNA sensing such as the absent in melanoma 2 (AIM2) and STING proteins. Since the cellular defense is triggered by the recognition of the sequence/pattern of nucleic acids that are specific for particular infectious agents, it is challenging to extrapolate these findings to nucleic acid-based nanoparticles. In addition, the structure of viral genomes typically cannot be used for the design of therapeutically useful nanoparticles. nucleic acid therapeutic is determined by the nature of the receptor, cell type, and the physiological status of the cell [75] . Furthermore, some receptors are internalized via multiple pathways and the route can be influenced by the concentration of the ligand [76] . However, how naked nucleic acids can cross the endosome membrane is currently unclear.
In an extensive safety evaluation of the anti PSMA A9g RNA aptamer over the course of a 4-week treatment Dassie et al. found no apparent change in the general appearance, behavior, and weight of treated mice [77] . Also, no significant effects on blood cells or pathological abnormalities in major organs were observed. Monitoring of A9g labeled with a near-infrared fluorophore revealed an even distribution of the aptamer throughout the body of the mouse 5 minutes after administration. After 8 hours both the A9g aptamer and the control A9g.6 aptamer were cleared from the circulation and only the A9g aptamer was retained in PSMA+ tumors for up to 72 hours. The 2'-F modified A9g aptamer was stable in 100% human serum for up to 8 hours after which its degradation occurred. However, 50% of the RNA survived for 7 days. Finally, the authors examined the potential of immune activation after the systemic administration of RNA aptamers. Although expression of inflammatory cytokines, interferons, and viral RNA recognition genes in the spleen and liver were not increased after treatment with the A9g aptamer, a slight increase in both IFN-β/γ was observed in the spleens of mice treated with the non-binding A9g.6 aptamer. Since the A9g.6 aptamer differs from the A9g aptamer by only one nucleotide the most likely increase in IFN-β/γ is due to the structural differences of the aptamers, indicating that it may be difficult to infer general conclusions about immunostimulatory properties of individual RNA or DNA particles based on published work.
Conflict of interest: Authors state no conflict of interest

